Trial · NCT01524978
Participant flow33
How many started, completed or left each group, period by period.
1 to 20 of 33
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib | 62 | |
| Overall Study | STARTED | Cohort 2: Ovarian Cancer - Vemurafenib | 4 | |
| Overall Study | STARTED | Cohort 3a: Colorectal Cancer - Vemurafenib | 10 | |
| Overall Study | STARTED | Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab | 27 | |
| Overall Study | STARTED | Cohort 4: Cholangiocarcinoma - Vemurafenib | 9 | |
| Overall Study | STARTED | Cohort 6: Multiple Myeloma - Vemurafenib | 9 | |
| Overall Study | STARTED | Cohort 7a: ECD/LCH - Vemurafenib | 26 | |
| Overall Study | STARTED | Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib | 12 | |
| Overall Study | STARTED | Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib | 12 | |
| Overall Study | STARTED | Cohort 7d: Early Stage Astrocytoma - Vemurafenib | 9 | |
| Overall Study | STARTED | Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib | 28 | |
| Overall Study | COMPLETED | Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 2: Ovarian Cancer - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 3a: Colorectal Cancer - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab | 0 | |
| Overall Study | COMPLETED | Cohort 4: Cholangiocarcinoma - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 6: Multiple Myeloma - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 7a: ECD/LCH - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib | 0 | |
| Overall Study | COMPLETED | Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01524978/flow